Long-Term Liabilities: The sum of all non-current liabilities.
Aclaris Therapeutics, Inc. (ACRS) had Long-Term Liabilities of $29.80M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$3.30M |
|
$-14.61M |
|
$2.45M |
|
$0.85M |
|
$20.45M |
|
$-17.15M |
|
$2.54M |
|
$-14.61M |
|
$-14.61M |
|
$-14.61M |
|
$-14.61M |
|
$-14.61M |
|
$-14.61M |
|
$-17.15M |
|
$-17.04M |
|
122.62M |
|
122.62M |
|
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$100.59M |
|
$0.81M |
|
$74.94M |
|
$175.53M |
|
$25.63M |
|
-- |
|
|
Long-Term Liabilities |
$29.80M |
$55.43M |
|
$120.10M |
|
$120.10M |
|
$120.10M |
|
108.34M |
|
| Cash Flow Statement Financials | |
$-33.98M |
|
$38.00M |
|
$-3.33M |
|
$24.57M |
|
$25.26M |
|
$0.69M |
|
$9.46M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.92 |
|
-- |
|
-- |
|
-- |
|
-- |
|
25.77% |
|
-519.82% |
|
-519.82% |
|
-- |
|
-442.98% |
|
-442.98% |
|
$-34.07M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
0.70 |
|
127.67 |
|
-12.17% |
|
-12.17% |
|
-8.33% |
|
-12.17% |
|
$1.11 |
|
$-0.28 |
|
$-0.28 |
|